Hemostemix Secures $336,500 in Private Placement to Bolster Growth

Hemostemix ( (TSE:HEM) ) has shared an update.

Hemostemix Inc. announced the closure of a USD $336,500 private placement, issuing shares to CytoImmune Therapeutics LLC. The funds will be used for general working capital and business development. This move supports Hemostemix’s ongoing efforts to advance its stem cell therapy offerings and maintain its position in the healthcare sector.

Spark’s Take on TSE:HEM Stock

According to Spark, TipRanks’ AI Analyst, TSE:HEM is a Neutral.

Hemostemix’s stock is primarily hindered by its poor financial performance, characterized by no revenue and high leverage. The technical analysis points to positive momentum, but valuation concerns due to negative earnings are significant. The absence of earnings call data and impactful corporate events limits further insights.

To see Spark’s full report on TSE:HEM stock, click here.

More about Hemostemix

Hemostemix is an autologous stem cell therapy platform company founded in 2003, known for its development and commercialization of blood-based stem cell therapies, particularly angiogenic cell precursors (ACP-01). The company has completed multiple clinical studies and published results demonstrating the efficacy of ACP-01 in treating various cardiovascular conditions.

Average Trading Volume: 475,387

Technical Sentiment Signal: Sell

Current Market Cap: C$14.1M

Learn more about HEM stock on TipRanks’ Stock Analysis page.